Enlivex Therapeutics Shares Set to Reverse Split on Tuesday, October 27th (NASDAQ:ENLV)

Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) are scheduled to reverse split on Tuesday, October 27th. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, October 26th.

Enlivex Therapeutics Price Performance

Shares of NASDAQ ENLV traded down $0.03 during mid-day trading on Friday, reaching $0.17. 655,132 shares of the company’s stock were exchanged, compared to its average volume of 364,410. The firm has a market capitalization of $3.03 million, a price-to-earnings ratio of -0.02 and a beta of 1.42. Enlivex Therapeutics has a 52 week low of $0.17 and a 52 week high of $27.15. The firm has a 50-day moving average price of $0.79 and a two-hundred day moving average price of $6.06.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Tuesday, September 22nd. Zacks Research lowered shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $247.50.

Institutional Trading of Enlivex Therapeutics

Large investors have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in shares of Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after buying an additional 45,303 shares during the period. WINTON GROUP Ltd purchased a new position in shares of Enlivex Therapeutics during the 2nd quarter valued at $55,000. Finally, Susquehanna International Group LLP grew its stake in shares of Enlivex Therapeutics by 1,428.5% during the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after acquiring an additional 147,334 shares during the period. 1.02% of the stock is owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.